COMMUNIQUÉS West-GlobeNewswire

HEXO Corp annonce ses résultats du deuxième trimestre de l’exercice 2019
07/03/2019
GATINEAU, Québec, 07 mars 2019 (GLOBE NEWSWIRE) -- HEXO Corp (« HEXO » ou la « Société ») (TSX: HEXO ; NYSE-A : HEXO ) publiera ses résultats financiers du deuxième trimestre de l’exercice 2019, clos le 31 janvier, et [...]
Exactus Announces Retirement of Remaining Convertible Notes
07/03/2019
GLEN ALLEN, Va., March 07, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) , a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced that it has retired the last of [...]
Achillion Reports Fourth Quarter and Full Year 2018 Financial Results
07/03/2019
- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND [...]
Opthea’s Phase 2b Trial in Wet AMD Advances with a Second Positive Independent Safety Committee Recommendation
07/03/2019
MELBOURNE, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase 2b study of OPT-302 [...]
Ossur Hf : Results of the Annual General Meeting
07/03/2019
Announcement no. 16/2019 7 March 2019 Results of the Annual General Meeting Enclosed are the results of the Annual General Meeting of Össur hf. held today, Thursday 7 March 2019. The Icelandic Register of Enterprises [...]
111, Inc. Announces Fourth Quarter and Fiscal Year 2018 Unaudited Financial Results
07/03/2019
SHANGHAI, China, March 07, 2019 (GLOBE NEWSWIRE) -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results [...]
Athenex Regains Rights to KX2-391 in China
07/03/2019
BUFFALO, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
BrainStorm to Host Business Update Conference Call
07/03/2019
Tuesday, March 12th at 8.30am EDT NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating [...]
PDMR Dealing
07/03/2019
LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Helsinn initiates two new global Phase III studies with anamorelin
07/03/2019
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and [...]
About acquisition of significant shareholding
07/03/2019
On 20th of February 20, 2019 JSC Olainfarm has received a notification by Signe Baldere-Sildedze natural guardian of shareholder Anna Emīlija Maligina regarding increased material shareholding up till 7.8% from share [...]
AltoInvest purchases 131,000 warrants to be converted into C-RAD shares
07/03/2019
C-RAD today announces that AltoInvest purchased 131,000 warrants from C-RAD employees. The warrants are part of the employee warrant program approved by the Annual Shareholder Meeting in 2016. The warrants entitle [...]
Pixium Vision highlights conclusions of its KOL Meeting: Experts confirm PRIMA’s promises and potential to treat dry-AMD
07/03/2019
PRIMA, an unprecedented, innovative and evolutive “brain-machine” interface in ophthalmology PRIMA, bionic vision solution designed for advanced atrophic dry-AMD PRIMA clinical performance to date exceeded initial [...]
Pixium Vision présente les conclusions de son KOL meeting : les experts réaffirment les promesses de PRIMA et son intérêt dans la DMLA sèche
07/03/2019
PRIMA, une interface cerveau-machine inédite, innovante et évolutive en ophtalmologie PRIMA, une solution de vision bionique adaptée à la forme avancée de DMLA sèche PRIMA, des performances cliniques à ce jour [...]
L'essai clinique de Phase 2 sur le bermekimab montre une nouvelle norme de soins potentielle pour le traitement de l'hidrasadénite suppurée (HS), avec une réduction significative de la douleur sans associer d’antibiotiques
07/03/2019
- Avantage thérapeutique significatif obtenu, que les patients aient, ou non, déjà échoué au traitement avec un médicament biologique existant autorisé par la FDA. - 61 à 63 % des patients ont obtenu un score HiSCR [...]
ShockWave Announces Pricing of Initial Public Offering
07/03/2019
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public [...]
La collaboration entre Crown Bioscience et The Jackson Laboratory permet un accès mondial au modèle murin FATZO
07/03/2019
La collaboration continue facilite la distribution mondiale de l’obésité, des maladies métaboliques et du modèle NASH ainsi que l’approvisionnement prioritaire à la plateforme mondiale de maladies cardiovasculaires, de [...]
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
07/03/2019
BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
MRI Interventions, Inc. to Announce Fourth Quarter and Full Year 2018 Results on March 11
06/03/2019
IRVINE, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene [...]

Pages